FDA announces Class I recall of pacemakers | Johnson & Johnson resumes PFA rollout | LAAO or DOAC? AI can help

These safety issues have been linked to more than 800 injuries and two deaths. It is possible, the FDA warned, that some patients may require a device to be removed and replaced. 

Johnson & Johnson MedTech has resumed the U.S. rollout of its Varipulse PFA system, sharing new warnings to help physicians. 

It can be challenging to know which AFib patients are the best candidates for LAAO. A new algorithm out of Mayo Clinic aims to address that problem. 

The FDA has already shown great interest in the drug, which is designed to help AFib patients reduce their stroke and systemic embolism risks.

The difference in atrial fibrillation risk was unexpected, surprising researchers.

Just a small fraction of the people tracking their own heart health are actually doing anything with the data, according to a new survey commissioned by The Ohio State University Wexner Medical Center.

A care team in Illinois has performed the first heart procedure of its kind on a two-year-old patient diagnosed with Brugada syndrome.